Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
Central Nervous System Drug Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, China.
Oxid Med Cell Longev. 2022 Feb 22;2022:3723567. doi: 10.1155/2022/3723567. eCollection 2022.
Parkinson's disease (PD) is a complex neurological disorder characterized by motor and nonmotor features. Although some drugs have been developed for the therapy of PD in a clinical setting, they only alleviate the clinical symptoms and have yet to show a cure. In this study, by employing the model of PD, we found that ferulic acid (FA) significantly inhibited -synuclein accumulation and improved dyskinesia in NL5901 worms. Meanwhile, FA remarkably decreased the degeneration of dopaminergic (DA) neurons, improved the food-sensing behavior, and reduced the level of reactive oxygen species (ROS) in 6-OHDA-induced BZ555 worms. The mechanistic study discovered that FA could activate autophagy in , while the knockdown of 3 key autophagy-related genes significantly revoked the neuroprotective effects of FA in -synuclein- and 6-OHDA-induced models of PD, demonstrating that FA exerts an anti-PD effect via autophagy induction in . Furthermore, we found that FA could reduce 6-OHDA- or HO-induced cell death and apoptosis in PC-12 cells. Moreover, FA was able to induce autophagy in stable GFP-RFP-LC3 U87 cells and PC-12 cells, while bafilomycin A1 (Baf, an autophagy inhibitor) partly eliminated the protective effects of FA against 6-OHDA- and HO-induced cell death and ROS production in PC-12 cells, further confirming that FA exerts an anti-PD effect via autophagy induction in vitro. Collectively, our study provides novel insights for FA as a potent autophagy enhancer to effectively prevent neurodegenerative diseases such as PD in the future.
帕金森病(PD)是一种复杂的神经退行性疾病,其特征为运动和非运动症状。尽管一些药物已被开发用于临床治疗 PD,但它们仅能缓解临床症状,尚未显示出治愈效果。在本研究中,通过 PD 模型,我们发现阿魏酸(FA)可显著抑制α-突触核蛋白的积累并改善 NL5901 线虫的运动障碍。同时,FA 可显著减少多巴胺能(DA)神经元的变性,改善食物感知行为,并降低 6-OHDA 诱导的 BZ555 线虫中的活性氧(ROS)水平。机制研究发现,FA 可在 NL5901 线虫中激活自噬,而 3 个关键自噬相关基因的敲低则显著逆转了 FA 在α-突触核蛋白和 6-OHDA 诱导的 PD 模型中的神经保护作用,表明 FA 通过自噬诱导在 NL5901 线虫中发挥抗 PD 作用。此外,我们发现 FA 可降低 PC-12 细胞中 6-OHDA 或 H2O2 诱导的细胞死亡和细胞凋亡。此外,FA 可诱导稳定表达 GFP-RFP-LC3 的 U87 细胞和 PC-12 细胞中的自噬,而巴弗洛霉素 A1(Baf,自噬抑制剂)部分消除了 FA 对 6-OHDA 和 H2O2 诱导的 PC-12 细胞中细胞死亡和 ROS 产生的保护作用,进一步证实 FA 通过自噬诱导在体外发挥抗 PD 作用。总之,我们的研究为 FA 作为一种有效的自噬增强剂提供了新的见解,有望在未来有效预防 PD 等神经退行性疾病。